Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomised trials: a systematic review and network meta-analysis.

IF 7.2 2区 医学 Q1 ORTHOPEDICS
Tiago V Pereira,Pakeezah Saadat,Pavlos Bobos,Samir M Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry Dan Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Jason W Busse,Alex J Sutton,Peter Tugwell,Gillian A Hawker,Peter Jüni,Bruno R da Costa
{"title":"Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomised trials: a systematic review and network meta-analysis.","authors":"Tiago V Pereira,Pakeezah Saadat,Pavlos Bobos,Samir M Iskander,Nicolas S Bodmer,Martina Rudnicki,Henry Dan Kiyomoto,Thais Montezuma,Matheus O Almeida,Rishi Bansal,Pai-Shan Cheng,Jason W Busse,Alex J Sutton,Peter Tugwell,Gillian A Hawker,Peter Jüni,Bruno R da Costa","doi":"10.1016/j.joca.2024.08.014","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\r\nTo quantify the effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis through a systematic review and Bayesian random-effects network meta-analysis.\r\n\r\nDESIGN\r\nWe searched CENTRAL and regulatory agency websites (inception-2023) for large, English-language, randomised controlled trials (RCTs) (≥100 patients/group) examining any intra-articular intervention.\r\n\r\nPRIMARY OUTCOME\r\npain intensity.\r\n\r\nSECONDARY OUTCOMES\r\nphysical function and safety outcomes. Pain and function outcomes were analyzed at 2,6,12,24, and 52 weeks post-randomization, and presented as standardized mean differences (SMDs) (95% credible intervals, 95%CrI). The prespecified minimal clinically important between-group difference (MID) was -0.37 SMD. Safety outcomes were presented as odds ratios (OR) (95%CrI).\r\n\r\nFINDINGS\r\nAmong 57 RCTs (22,795 participants) examining 18 intra-articular interventions, usual care or placebo, treatment effects were larger in high-risk-of-bias trials (n=35) than low/unclear-risk-of-bias trials (n=22). In the main analysis (excluding high-risk-of-bias trials), triamcinolone had the highest probabilities of reaching the MID at weeks 2-6 (75.3% and 90%, respectively) with corresponding SMDs of -0.48 (95%CrI,-0.85 to -0.10) and -0.53 (95%CrI,-0.79 to -0.27) compared to placebo. Tr14/Ze14 homeopathic product showed therapeutic potential at week 6 compared to placebo (SMD:-0.42, 95%CrI,-0.71 to -0.11, 63.5% probability of reaching the MID). Hyaluronic acid had higher risk of dropouts due to adverse events (OR:2.01, 95%CrI,1.08 to 3.77) and serious adverse events (OR:1.86, 95%CrI,1.16 to 3.03) than placebo.\r\n\r\nCONCLUSION\r\nTriamcinolone had the highest probabilities to have a treatment effect beyond the MID at weeks 2-6. Large RCTs with lower risk of bias do not support the notion that 16 other intra-articular interventions assessed improve pain or function beyond placebo effects in knee or hip OA. Lack of evidence of long-term effectiveness underscores the need for further research beyond 24-52 weeks.","PeriodicalId":19654,"journal":{"name":"Osteoarthritis and Cartilage","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoarthritis and Cartilage","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.joca.2024.08.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

OBJECTIVE To quantify the effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis through a systematic review and Bayesian random-effects network meta-analysis. DESIGN We searched CENTRAL and regulatory agency websites (inception-2023) for large, English-language, randomised controlled trials (RCTs) (≥100 patients/group) examining any intra-articular intervention. PRIMARY OUTCOME pain intensity. SECONDARY OUTCOMES physical function and safety outcomes. Pain and function outcomes were analyzed at 2,6,12,24, and 52 weeks post-randomization, and presented as standardized mean differences (SMDs) (95% credible intervals, 95%CrI). The prespecified minimal clinically important between-group difference (MID) was -0.37 SMD. Safety outcomes were presented as odds ratios (OR) (95%CrI). FINDINGS Among 57 RCTs (22,795 participants) examining 18 intra-articular interventions, usual care or placebo, treatment effects were larger in high-risk-of-bias trials (n=35) than low/unclear-risk-of-bias trials (n=22). In the main analysis (excluding high-risk-of-bias trials), triamcinolone had the highest probabilities of reaching the MID at weeks 2-6 (75.3% and 90%, respectively) with corresponding SMDs of -0.48 (95%CrI,-0.85 to -0.10) and -0.53 (95%CrI,-0.79 to -0.27) compared to placebo. Tr14/Ze14 homeopathic product showed therapeutic potential at week 6 compared to placebo (SMD:-0.42, 95%CrI,-0.71 to -0.11, 63.5% probability of reaching the MID). Hyaluronic acid had higher risk of dropouts due to adverse events (OR:2.01, 95%CrI,1.08 to 3.77) and serious adverse events (OR:1.86, 95%CrI,1.16 to 3.03) than placebo. CONCLUSION Triamcinolone had the highest probabilities to have a treatment effect beyond the MID at weeks 2-6. Large RCTs with lower risk of bias do not support the notion that 16 other intra-articular interventions assessed improve pain or function beyond placebo effects in knee or hip OA. Lack of evidence of long-term effectiveness underscores the need for further research beyond 24-52 weeks.
基于大型随机试验的膝关节和髋关节骨关节炎关节内干预措施的有效性和安全性:系统综述和网络荟萃分析。
目的通过系统综述和贝叶斯随机效应网络荟萃分析,量化膝关节和髋关节骨关节炎关节内干预的有效性和安全性。设计我们检索了 CENTRAL 和监管机构网站(开始至 2023 年),以了解对任何关节内干预进行研究的大型英语随机对照试验 (RCT)(≥ 100 名患者/组)。疼痛和功能结果在随机后 2、6、12、24 和 52 周进行分析,以标准化均值差异 (SMD) (95% 可信区间,95%CrI)表示。预设的最小临床重要组间差异(MID)为-0.37 SMD。研究结果在57项研究(22795名参与者)中,对18种关节内干预、常规护理或安慰剂进行了研究,结果发现高偏倚风险试验(35例)的治疗效果大于低/不明确偏倚风险试验(22例)。在主要分析中(排除高偏倚风险试验),与安慰剂相比,曲安奈德在第2-6周达到MID的概率最高(分别为75.3%和90%),相应的SMD分别为-0.48(95%CrI,-0.85至-0.10)和-0.53(95%CrI,-0.79至-0.27)。与安慰剂相比,Tr14/Ze14 顺势疗法产品在第 6 周显示出治疗潜力(SMD:-0.42,95%CrI,-0.71 至 -0.11,63.5% 的概率达到 MID)。与安慰剂相比,透明质酸因不良事件(OR:2.01, 95%CrI,1.08-3.77)和严重不良事件(OR:1.86, 95%CrI,1.16-3.03)导致的退出风险更高。偏倚风险较低的大型 RCT 并不支持这样的观点,即在膝关节或髋关节 OA 中,其他 16 项关节内干预评估对疼痛或功能的改善超过了安慰剂的效果。由于缺乏长期有效性的证据,因此有必要在24-52周后进一步开展研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Osteoarthritis and Cartilage
Osteoarthritis and Cartilage 医学-风湿病学
CiteScore
11.70
自引率
7.10%
发文量
802
审稿时长
52 days
期刊介绍: Osteoarthritis and Cartilage is the official journal of the Osteoarthritis Research Society International. It is an international, multidisciplinary journal that disseminates information for the many kinds of specialists and practitioners concerned with osteoarthritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信